Axel Müller has been appointed chief executive officer of SkyePharma Plc, replacing Ken Cunningham who is stepping down in order to focus on his non-executive directorships at other companies. Dr Müller, a German national, will be based principally in Muttenz, Switzerland, where SkyePharma has its main research and development activities. The new chief executive was most recently CEO at Acino Holding AG, a Swiss-based specialist pharmaceutical company and before that president of Siegfried Generics, a unit of Siegfried AG. Dr Müller holds a PhD in pharmacology from Tübingen University.
Copyright 2010 Evernow Publishing Ltd